

OMVOH (MIRIKIZUMAB-MRKZ) ORDERS

P: 877.365.5566 | **F:** 855.889.2946

PATIENT INFORMATION	ON: Fax completed form, ins	urance information	n, and clinical documentation	n to 855.889.2946
Patient Name:		DOB:	Phone:	
	herapy 🗆 Continuing Therapy	y Next Treat	ment Date:	
MEDICAL INFORMATION	JN			
Patient Weight: lbs	s. (required) Allergies:			
Diagnosis: □ Ulcerative Co	olitis 🗆 Other:			
ICD-10 Code:	_			
THERAPY ORDER				
Omvoh				
☐ IV induction dos	e: 300mg IV at week 0, 4	, and 8		
	se: 200mg subcutaneousl ar (to be evaluated by Pa	_	_	ks
Lab Orders:				
LFTs and Bilirubi	in should be monitored at baselir	ne, during first 2	4 weeks of treatment, ar	nd periodically
Lab frequency: ☐ Prio	or to 4 and 8 week dose	∃ Other:		
		-		
Required labs to be dr	rawn by: □ Paragon □ Re	eferring Prov	ider	
Other orders:				
 Home IV Biologic Ana-kit Orders Epinephrine: >30kg (>66 Diphenhydramine: Admini NS 0.9% 1000mL IV bolus Home biologic injection Ana-kit Dispense per protocol Ep 	Slbs): EpiPen 0.3mg or compounde ister 25-50mg orally OR IV (adult) s per protocol PRN (adult) t (adult):	ed syringe IM or su	ubQ; may repeat in 5-10 m	ninutes x1
Flush orders: NS 1-20mL pre/po	ost infusion PRN and Heparin 10U/r	mL or 100U/mL p	er protocol as indicated P	RN
PROVIDER INFORMAT	ION			
agent in dealing with medical and prescription	you are authorizing <i>Paragon Healthcare, Inc.</i> and it insurance companies, and to select the preferred	site of care for the patien	t.	
Provider NPI:	Phone: Signature:		Dat Contact Person:	e:
☐ Opt out of Paragon select	Signature: Phone: Fax: ting site of care (if checked, pla	ease list site of	care):	
PREFERRED LOCATIO				
				0K%0
City:	State:	Vie	w our locations here:	

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





COMPREHENSIVE SUPPORT FOR OMVOH THERAPY

PATIENT INFORMATION:					
Patient Name: DOB:					
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROV	AL				
☐ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)					
\square Include patient demographic information and insurance information					
☐ Include patient's medication list					
Supporting clinical notes to include any past tried and/or failed therapies, intolerance benefits, or contraindications to conventional therapy	e,				
☐ Does the patient have a contraindication/intolerance or failed trial to corticosterior or immunomodulators (i.e., 6-MP, azathioprine, budesonide)? ☐ Yes ☐ No If yes, which drug(s)?	oids				
□ Does the patient have a contraindication/intolerance or failed trial to any biologic (i.e., Humira, Remicade, Stelara, Cimzia)? □ Yes □ No If yes, which drug(s)?					
☐ Include labs and/or test results to support diagnosis					
If applicable - Last known biological therapy: and last date received If patient is switching to biologic therapies, please perform a wash out period of weeks prior to starting Omvoh.	d: -				
Other medical necessity:					
REQUIRED PRE-SCREENING					
☐ TB screening test completed - attach results ☐ Positive ☐ Negative					
☐ Baseline liver function tests and bilirubin - attach results					
If TB results are positive - please provide documentation of treatment or medical clearance, and a negative CXR					

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance